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We, herein, present an unusual case of porphyria
diagnosed during the puerperium period in our health
care service.
METHODS
Systematic Medline, PubMed, Cochrane, and
uptodate search were done based on the terms preg-
nancy, puerperium, porphyria, acute crisis during the
last five years. We then took the seven most relevant
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SUMMARY
The porphyrias are a group of diseases caused by a deficiency of enzymes responsible for the synthesis of heme, that can
lead to severe disease that requires early diagnosis to avoid complications. The frequency of the disease is low and its
association with pregnancy unusual, but it is a good time for patients carrying develop the disease or suffer an exacerbation
of the same, hence the vital importance of prophylaxis of the factors risk.
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RESUMEN
Las porfirias son un grupo de enfermedades producidas por un déficit de las enzimas encargadas de la síntesis del hemo,
que pueden dar lugar a un cuadro clínico grave que requiere un  diagnóstico precoz para evitar complicaciones. La frecuencia
de la enfermedad es baja y su asociación con el embarazo inusual, pero es un buen momento para que las pacientes portadoras
desarrollen la enfermedad o sufran una exacerbación de la misma, de ahí la importancia vital de la profilaxis de los factores
de riesgo.
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articles according to the qualification of the paper
where it was published.
CLINICAL CASE
A 34 year old Caucasian woman presented intense
abdominal pain during immediate puerperium.
Family background: of no interest
Personal background: allergic to penicillin, panto-
micine, and aspirin. The patient is reportedly an ex
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smoker (ten cigarettes per day). Operated for menin-
goplasty and uses a prosthetic eyeball, secondary to
destruction during the M-11 terrorist attack in Madrid,
Spain. She received psychiatric treatment for post-
traumatic stress syndrome.
In July 2008, the patient attended emergency room
consultation for abdominal pain and also located in the
episiotomy. Pain did not respond to pain killers
previously prescribed on two occasions. Physical exa-
mination revealed a slight indurated episiotomy scar
with no signs of infection or hematoma. All tests,
including blood count, vital constants, and gynecological
ultrasound, were normal. We decided on hospital
admission in our service with the following diagnosis:
incipient episiotomy infection and treated the patient
with antibiotics and pain killers.
During the hospital stay, the patient did not respond
to pain killers and was evaluated by psychiatric and
anesthesiology services. She was finally diagnosed
with adjustment disorder with anxiety and depression
features.
Four days later, she was admitted to the intensive
care unit after having three episodes of generalized
seizures and was treated with phenytoin, midazolam,
and manitol after dismissing brain damage and menin-
gitis. The patient was diagnosed with Recurrent Seizures
and readmitted to the hospital ward.
During hospitalization, levels of TSH, ACTH, LF,
FSH, thyroxine, and cortisol were determined to dismiss
Sheehan syndrome; all levels were reported normal.
CT scan was performed because of abdominal-
pelvic constipation objecting feces up to rectum-sigma
union and distended intestinal bowel loops.
Finally, she began to present a progressive lethargic
state with disorientation in time related to severe
hyponatremia (109.8 mmol/l). She was then readmitted
to the ICU, proposing Acute Neurovisceral Porphyria
crisis demonstrated with the following values of
porphyrins in urine.
ALA: 40.8 mg/24 h (<7 mg/per day)
PBG: 30.8 mg/24 h (<2 mg/per day)
Total porphyrins (uro/copro) 4424 mg/24 h
(15-300 mg/per day)
Copro-porphyrins 3920mg/24 h (<250)
Uro-porphyrins 504 (<50)
With these results, we started treatment with
intravenous infusion of heme alginate, 150 mg/24 h
during four days. With non-established porphyria and
given the clinical stability, the patient was discharged
from the hospital for future follow up.
COMMENTS
Porphyrias are a variety of disorders, inherited or
not, involving the activity of enzymes involved in the
synthesis of the heme group and other hemoproteins.
As a consequence of its deficiency, intermediate toxic
metabolites build up and are stored in different types of
tissues in our body, developing the neurovisceral
symptoms like abdominal pain, psychiatric signs, and
neurological and photosensitive skin signs.
Diagnosis of each type of deficiency is given by
identifying the metabolite produced in excess in the red
blood cells, plasma, feces, or urine, as in our case. Most
of them can be diagnosed by measuring the exact
enzyme activity in the appropriate tissue1. Most mammal
cells are able to synthesize heme, although it mostly
occurs in the bone marrow, up to 85%.
Frequency is estimated in 1/10.000 but this can vary
depending on geography2. Not all carriers of the disease
develop clinical findings and there are significant
interactions between the defect and environmental
factors2.
There are as many porphyrias as enzymes involved
in the metabolic route with exception of the first enzyme,
α-Aminolevulinic acid (ALA), whose synthesis is
increased in compensatory manner as it is normally
inhibited by its final product, heme1,3.
We found deficiencies of ALA dehydratase that
correlates with acute intermittent porphyria, both with
neurological symptoms.
Others like congenital erythropoietic porphyria
(CEP), porphyria cutanea tarda (PCT), and erythro-
poietic protoporphyria deal with skin photo-
sensitivity1,3.
Our case offers some doubts about classification;
first, because a second determination of urine porphyrins
was made when the patient had already started treatment.
In the second place, because our lab results could well
determine mixed porphyria that appear to have acute
crisis.
After the clinical findings and high incidence, the
patient was initially diagnosed as acute intermittent
porphyria, also called Swedish porphyria. It is a
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metabolic error that affects more women than men and
is inherited in autosomal dominant manner, causing a
partial deficit in the porphobilinogen deaminase enzyme.
Presentation with abdominal pain is well known and
up to 95% of these patients start with this symptom.
Abdominal symptoms are followed by progressive
neuro-psychiatric features (periphery motor neuropathy,
breathing paralysis, seizures, or loss of consciousness).
Other clinical findings that can appear during the
process are tachycardia, hypertension, and bladder
retention; seizures are usually due to severe hypo-
natremia. It is essential to understand that seizures can
occur and that antiepileptic medications can be harmful1.
Acute intermittent porphyria should always be
considered in the differential diagnosis of abdominal
pain presented with neuro-psychiatric features, even if
there is a previous family history or not. Once we have
the diagnosis, the family should be tested to determine
PBGD levels4,5.
Prenatal diagnosis is of interest, especially in
determining erythropoietic porphyria. Techniques that
may be involved are measuring porphyrins in amniotic
fluid and amniotic cell culture1. Genetic counseling is
important, specifically when both parents carry the
affected gene5. Oral contraceptives should be avoided
in patients and first grade relatives, as they can promote
acute crisis6.
Treatment is symptomatic and oriented to improving
the skin condition and clinical manifestations. It is
important to avoid precipitating factors involved in
developing acute crisis. Some examples are estrogens,
valproic acid, barbiturates, sulfonamides, and hydan-
toins. Other factors involved in acute crisis are alcohol,
hypocaloric diets, and infections5.
The objective of treatment with hematine is to fill up
deposits with free-regulating heme. Secondary effects
are due to its degradation products. There is also heme
arginate, which is more stable with a recommended
dose of 2-3 mg/kg/day during four consecutive days
administered in slow infusion during 15-20 minutes in
a saline solution. Effects on the fetus are unknown;
therefore, this treatment should not be used during
pregnancy2,5.
Two vulnerable moments are at the beginning of
pregnancy and puerperium. It is recommended to avoid
pregnancy until at least 18 months have passed without
symptoms4,5.
Glucose solution is also included in therapy and it is
able to stop an acute crisis as it inhibits ALA activity.
It should be set up in all conflictive situations like labor,
surgery, etc5.
DISCUSSION
As we have described, there are serious difficulties
in diagnosing this illness during pregnancy and
puerperium. Our patient was misdiagnosed several
times4.
Information about porphyria and pregnancy is scant
and insufficient. The information we have is from
attending on individual cases as the frequency of the
affection is low and association with pregnancy is rare.
This complicates our knowledge on the behavior of the
illness in pregnant patients. What should not be forgotten
is that hormonal changes, prolonged fasting due to
hyperemesis, and several drugs can initiate an acute
porphyrinic attack.
Revision of the literature concludes that the illness
can worsen because of symptomatic exacerbations,
estimated in 50% of cases7.
Mothers’ mortality rates range from 27% to 42.5%7.
Symptomatic exacerbations are generally due to
exposing the patients to certain drugs that can modify
the course of the pregnancy, resulting in abortion,
preterm births, and other pregnancy complications. Up
to 60% of pregnancy complications happen at the
beginning, in early gestational ages2.
Nearly 15% of the complications occur during the
second trimester and are generally severe. Although
during the last weeks of pregnancy, women present
high ALA and PBG levels in urine, in porphyrinic
pregnant women the levels tend to be higher3.
An estimated 25% of the complications happen
during puerperium. Maximum risks periods seem to be
early gestational ages and puerperium. Children from
porphyrinic mothers are normal when born, independent
of their genotype, although there has evidence of a
higher frequency of low birth weight and stillbirths4.
CONCLUSIONS
It is important to highlight the possibility of
diagnosing this illness during pregnancy and puerperium
in fertile women who are carriers of the defect, as this
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period is of special risk. Diagnosis should be performed
by measuring excretion of porphyrins or, better still, by
running genetic tests. Thus, we will be able to avoid
precipitating factors.
Porphyria can be a negative influence in pregnancy
and, in turn, pregnancy can precipitate acute crisis.
Women who carry the deficiency should be well
informed about risks and receive health information
about the symptoms and precipitating factors so they
can have healthier pregnancies and healthier children.
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